ABSTRACT
BACKGROUND: Seroepidemiological studies provide important insight into the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in our society. We aimed to determine seropositivity of SARS-CoV2 antibodies and its cross-sectional correlates in a large cohort of blood donors. METHODS: In this observational cohort study, we tested healthy blood donors residing in Tyrol, Austria, for SARS-CoV2 antibodies using the Abbott SARS-CoV2 IgG chemiluminescent microparticle immunoassay. We estimated 95% confidence intervals (95% CI) of seroprevalences using bootstrapping and tested for differences by participant characteristics using logistic regression. FINDINGS: Between 8 June and 4 September 2020, we screened 5345 healthy individuals at local blood donor sessions (mean age 42.7 years, SD 13.5 years, 46.7% female). Overall seroprevalence was 3.1% (95% CI 2.7-3.6%, 165 cases), which is 5.1-fold higher (95% CI 4.5-6.0%) than the case number identified by the health authorities in the state-wide testing program (0.6%; 4536 out of 757,634). Seroprevalence was higher in the district Landeck (16.6%, Pâ¯< 0.001) and in individuals aged <â¯25 years (4.7%, Pâ¯= 0.043), but did not differ by gender, blood types, or medication intake. The odds ratio for seropositivity was 2.51 for participants who had travelled to Ischgl (1.49-4.21, Pâ¯= 0.001), 1.39 who had travelled to other federal states (1.00-1.93, Pâ¯= 0.052), and 2.41 who had travelled abroad (1.61-3.63, Pâ¯< 0.001). Compared to participants who had a suspected/confirmed SARS-CoV2 infection but were seronegative, seropositive participants more frequently reported loss of smell (odds ratioâ¯= 2.49, 1.32-4.68, Pâ¯= 0.005) and taste (odds ratioâ¯= 2.76, 1.54-4.92, Pâ¯= 0.001). CONCLUSION: In summer 2020, SARS-CoV2 seroprevalence in Tyrolean blood donors was 3.1%. Our study revealed regional variation and associations with young age, travel history and specific symptoms.